Although POH has said that Mylan didn’t advise its product registration or launch plans, you would think that some assurance/evidence of significant development progress had been provided by Mylan because in April 2016 (Annual Report), reference was made to “royalties due quarterly after the expected launch in first quarter of 2017.”
By April 2017, the Company’s expectations had changed. It now referred to valuation modelling based on “an assumption that due to the commercialisation partner for TPM/Daptomycin not having advised a launch date that an inference can be drawn that this partner does not have the intention to launch the product.”
POH Price at posting:
2.7¢ Sentiment: Hold Disclosure: Held
(20min delay)
